The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.

In a method for oxidizing 1,1-bis-(3,4-dimethylphenyl)-alkane with nitric acid in a pressure vessel to produce 3,3′,4,4′-benzophenone tetracarboxylic acid with concurrent formation of nitric oxide, passing nitric oxide from the pressure vessel into an absorption vessel and reacting nitric oxide in the absorption vessel with molecular oxygen and water to produce an aqueous nitric acid solution prevents discharge of nitric oxide, avoids the risk of oxygen inhibiting the nitric acid oxidation and reduces nitric acid consumption when the nitric acid from the absorption vessel is used for oxidizing the 1,1-bis-(3,4-dimethylphenyl)-alkane.

In a method for oxidizing 1,1-bis-(3,4-dimethylphenyl)-alkane with nitric acid in a pressure vessel to produce 3,3′,4,4′-benzophenone tetracarboxylic acid with concurrent formation of nitric oxide, passing nitric oxide from the pressure vessel into an absorption vessel and reacting nitric oxide in the absorption vessel with molecular oxygen and water to produce an aqueous nitric acid solution prevents discharge of nitric oxide, avoids the risk of oxygen inhibiting the nitric acid oxidation and reduces nitric acid consumption when the nitric acid from the absorption vessel is used for oxidizing the 1,1-bis-(3,4-dimethylphenyl)-alkane.

Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.

The present invention relates to polyhydroxylated benzophenone compounds useful in the treatment of neurodegenerative, neurological, psychiatric, and cognitive diseases, in particular those associated with a deficiency in HDAC1 deacetylase activity.

Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.